Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.58 |
| ▸ | SKP1 | P63208 | 2/20 | 0.58 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.53 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ADK | P55263 | 1/20 | 0.48 |
| ▸ | WNT3A | P56704 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19598713 | 0.90 | HRH3 (0.56) | CKS1BSKP1SKP2HRH3GPR119 | |
| SCHEMBL31284589 | 0.90 | HRH3 (0.56) | CKS1BSKP1SKP2HRH3GPR119 | |
| SCHEMBL8506021 | 0.89 | GPR119 (0.67) | HRH3GPR119DDB1CRBN | |
| SCHEMBL31458395 | 0.89 | HRH3 (0.58) | CKS1BSKP1SKP2HRH3GPR119 | |
| SCHEMBL8351634 | 0.89 | HRH3 (0.53) | CKS1BSKP1SKP2HRH3GPR119 | |
| SCHEMBL31752803 | 0.89 | TBK1 (0.58) | CKS1BSKP1SKP2HRH3GPR119 | |
| SCHEMBL30313118 | 0.88 | NPC1 (0.62) | CKS1BSKP1SKP2HRH3GPR119 | |
| SCHEMBL18436901 | 0.88 | MAP4K4 (0.54) | CKS1BSKP1SKP2HRH3GPR119 | |
| SCHEMBL19283866 | 0.88 | NPC1 (0.62) | CKS1BSKP1SKP2HRH3GPR119 | |
| SCHEMBL31701039 | 0.86 | HRH3 (0.59) | CKS1BSKP1SKP2HRH3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20250360219-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | ARVINAS OPERATIONS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | ARVINAS OPERATIONS INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-05-15 | — | — | US | disclosed |
| US-12239711-B2 | Cereblon ligands and bifunctional compounds comprising the same | ARVINAS OPERATIONS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4509184-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2025-01-30 | — | — | US | disclosed |
| WO-2025022093-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2025-01-30 | — | — | WO | disclosed |
| WO-2010040663-A1 | PYRROLIDINE N-BENZYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-15 | — | — | WO | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20090291965-A1 | Histone Deacetylase Inhibitors With Aryl-Pyrazolyl-Motifs | MERCK SHARP & DOHME LLC | 2009-11-26 | — | — | US | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| EP-1945617-A2 | HISTONE DEACETYLASE INHIBITORS WITH ARYL-PYRAZOLYL MOTIFS | Merck & Co., Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| WO-2007055941-A2 | HISTONE DEACETYLASE INHIBITORS WITH ARYL-PYRAZOLYL MOTIFS | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360219-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | CKS1B 185/4885SKP1 2663/4885SKP2 160/4885 |
| US-12239711-B2 | Cereblon ligands and bifunctional compounds comprising the same | CRBN, CBL, MDM2 | CKS1B 185/4885SKP1 2663/4885SKP2 160/4885 |
| US-20250313547-A1 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | CRBN, CBL, MDM2 | CKS1B 185/4885SKP1 2663/4885SKP2 160/4885 |
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | BCL2, BCL2L2, BCL2L1 | CKS1B 210/4885SKP1 1991/4885SKP2 289/4885 |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | CKS1B 475/4885SKP1 3427/4885SKP2 82/4885 |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | CKS1B 3383/4885SKP1 3631/4885SKP2 4584/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CKS1B 1016/4885SKP1 266/4885SKP2 1519/4885 |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | CKS1B 198/4885SKP1 4048/4885SKP2 149/4885 |
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | CKS1B 1562/4885SKP1 2688/4885SKP2 2403/4885 |
| US-20090291965-A1 | Histone Deacetylase Inhibitors With Aryl-Pyrazolyl-Motifs | HDAC1, HDAC3, HDAC5 | CKS1B 146/4885SKP1 932/4885SKP2 304/4885 |
| US-12441708-B2 | Cereblon ligands and bifunctional compounds comprising the same | CRBN, CBL, MDM2 | CKS1B 185/4885SKP1 2663/4885SKP2 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.